MA-0204 |
| カタログ番号GC19450 |
MA-0204 は、ヒト、マウス、ラットの PPARδ に対してそれぞれ 0.4 nM、7.9 nM、10 nM の EC50 を持つ、強力で選択性の高い経口投与可能なペルオキシソーム増殖因子活性化受容体δ (PPARδ) モジュレーターです。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2095128-17-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MA-0204 is a potent, highly selective PPARδ modulator with EC50s of 0.4, 7.9 and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD) [1].
MA-0204 is >10,000-fold selective for activation of PPARδ over PPARα and PPARγ receptors. It has EC50s of 6,990 nM and more than 100,000 nM for human PPARα and PPARγ, respectively. MA-0204 exhibits high protein binding to mouse plasma, good permeability and low potential for efflux. C[1].MA-0204 (1.2-12 nM) improves fatty acid oxidation in DMD patient muscle myoblasts mice[1].MA-0204 (0.04-40 nM) engages target gene expression in DMD patient muscle myoblasts[1].
PPARδ (30, 100 mg/kg) increases target gene transcription in the muscle[1].
[1]. Lagu B, et al. Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD). ACS Med Chem Lett. 2018 Jul 31;9(9):935-940.
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *